Neuphoria Therapeutics Inc. (NEUP)
NEUP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1191070/000119312526395536/0001193125-26-395536-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | NEUP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001191070 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Australia |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $1.2M |
| Net income | -$13.5M |
| Operating income | -$16.5M |
| Net margin | -1145.7% |
| Operating margin | -1401.1% |
| Revenue growth | -92.5% |
| Cash | $19.9M |
| Total assets | $28.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Consequently, management has determined there is no substantial doubt regarding the Company's ability to continue as a going concern for the twelve month period from the date these financial statements are issued." | 10-K 2026-09-18 |
| Cash and burn | $19.9M cash; operating cash flow -$3.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 5,411,334 (2026-09-17); 2,357,613 a year earlier; 1,486,735,424 three years earlier. 3y figure adjusted for split (1-for-12 overall). | Cover page 2026-09-17 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2024-12-24 | Source 2024-12-24 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Wolf & Company, P.C., Boston, Massachusetts, United States | PCAOB Form AP 2026-09-29 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | Not filed | -$4.9M | $1.2M | $19.9M | No debt tags | $1.2M | 10-K 2026-09-18 |
| Q3 2026 2026-03-31 | Not filed | -$505K | -$3.3M | $19.4M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q2 2026 2025-12-31 | Not filed | $1.9M | -$6.4M | $22.2M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q1 2026 2025-09-30 | Not filed | -$9.9M | -$3.8M | $13.6M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-06-30 | -$13K | -$8.9M | -$3.6M | $14.2M | No debt tags | $15.6M | 10-K 2025-09-29 |
| Q3 2025 2025-03-31 | $15.0M | $11.3M | $11.5M | $17.0M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q2 2025 2024-12-31 | $663K | -$1.9M | -$3.4M | $4.3M | No debt tags | Needs four quarters | 10-Q 2026-02-17 |
| Q1 2025 2024-09-30 | Not filed | -$805K | -$4.4M | $8.1M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2025-11-14 |
| Latest annual report | 10-K | 2026-09-18 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-23 |
| Latest proxy | DEFA14A | 2026-09-18 |
Source: SEC EDGAR submissions feed, 421 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.3% |
| 1 month | -24.8% |
| 3 months | -33.4% |
| Year to date | -34.3% |
| 1 year | -46.3% |
| From 52-week high | -53.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CMMB | Chemomab Therapeutics Ltd. American Depositary Share | $1.62 | +5.88% | $13.0M |
| MRKR | Marker Therapeutics Inc. | $0.8286 | -4.76% | $13.8M |
| KYNB | Kyntra Bio Inc. | $3.20 | -8.31% | $13.0M |
| ALLR | Allarity Therapeutics Inc. | $0.8752 | -8.24% | $13.9M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| OPTH | Optimi Health Corp. Common Shares | $2.15 | -4.44% | $12.3M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier